In a word, our study first reveals that the high expression of TP53INP2 mediated by FTO and cytoplasmic delocalization of TP53INP2 modulated by NPM1-mA jointly facilitates autophagic pro-survival, which provides a new theoretical basis for NPM1-mutated AML therapy. The gene discussed is NPM1; the disease is acute myeloid leukemia.